• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Evofem Biosciences Inc. (Amendment)

    2/14/22 3:30:22 PM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EVFM alert in real time by email
    SC 13G/A 1 tm226115d25_sc13ga.htm SC 13G/A

     

    CUSIP No: 30048L104

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    Evofem Biosciences, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    30048L104
    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨  Rule 13d-1(b)
      x  Rule 13d-1(c)
      ¨  Rule 13d-1(d)

     

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No: 30048L104

     

      (1)

    NAMES OF REPORTING PERSONS

     

    CVI Investments, Inc.

     

      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
          (a)    ¨
          (b)    ¨
           
      (3) SEC USE ONLY
         
      (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    (5) SOLE VOTING POWER
     
    0
     
    (6) SHARED VOTING POWER **
     
    10,000,000
     
    (7) SOLE DISPOSITIVE POWER
     
    0
     
    (8) SHARED DISPOSITIVE POWER **
     
    10,000,000

      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
        10,000,000
         
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨ 
         
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
         
        5.8%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
        CO
         

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 30048L104

     

      (1)

    NAMES OF REPORTING PERSONS

     

    Heights Capital Management, Inc.

     

      (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
          (a)    ¨
          (b)    ¨
           
      (3) SEC USE ONLY
         
      (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    (5) SOLE VOTING POWER
     
    0
     
    (6) SHARED VOTING POWER **
     
    10,000,000
     
    (7) SOLE DISPOSITIVE POWER
     
    0
     
    (8) SHARED DISPOSITIVE POWER **
     
    10,000,000

     

      (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
        10,000,000
         
      (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨ 
         
      (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
         
        5.8%
         
      (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
        CO
         

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 30048L104

     

    Item 1.

     

    (a)Name of Issuer

     

    Evofem Biosciences, Inc. (the “Company”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    12400 High Bluff Drive, Suite 600, San Diego, CA 92130

     

    Item 2(a). Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.0001 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b). Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c). Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d) Title of Class of Securities

     

    Common stock, $0.0001 par value per share

     

    Item 2(e) CUSIP Number

     

    30048L104

     

     

     

     

    CUSIP No: 30048L104

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).

     

    (b) ¨  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c) ¨  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) ¨  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e) ¨  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f) ¨  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g) ¨  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h) ¨  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i) ¨  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j) ¨  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

    (k) ¨  Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The number of Shares reported as beneficially owned consists of Shares issuable upon the exercise of warrants to purchase Shares.

     

    The Company’s Prospectus Supplement (to Prospectus dated August 5, 2021, Registration No. 333-258321), filed on January 13, 2022, indicates there were 162,500,425 Shares outstanding as of December 31, 2021.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

     

     

     

    CUSIP No: 30048L104

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No: 30048L104

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 11, 2022

     

    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.
         
    By: Heights Capital Management, Inc.
    pursuant to a Limited Power of Attorney, a copy of which was previously filed
      By: /s/ Brian Sopinsky
      Name: Brian Sopinsky
      Title: Secretary

     

    By: /s/ Brian Sopinsky  
    Name: Brian Sopinsky  
    Title: Secretary  

     

     

     

     

    CUSIP No: 30048L104

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney*
    II   Joint Filing Agreement*
         

    *Previously filed 

     

     

     

    Get the next $EVFM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVFM

    DatePrice TargetRatingAnalyst
    3/4/2022$0.50 → $0.53Underweight
    Morgan Stanley
    11/16/2021$2.50 → $2.00Buy
    HC Wainwright & Co.
    10/21/2021$4.00 → $2.50Buy
    HC Wainwright & Co.
    10/14/2021$0.80Equal-Weight → Underweight
    Morgan Stanley
    8/12/2021$3.00 → $1.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $EVFM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

    -- Evofem now holds eleven Orange Book - listed patents covering SOLOSEC into late 2041 -- SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCID: EVFM) today announced that a newly-issued U.S. patent which covers SOLOSEC® (secnidazole) 2 g oral granules and one of its labeled indications is now listed in the U.S. Food and Drug Administration (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">

    8/19/25 9:39:00 AM ET
    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

    -- Increased Net Sales and Improved Loss from Operations in Q2 2025 vs. Prior Year Quarter -- -- Evofem Advances Plans for Special Meeting of Stockholders to Approve the A&R Merger Agreement and Become a Wholly-owned Subsidiary of Aditxt --  SAN DIEGO, Aug. 14, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the three- and six-month periods ended June 30, 2025 and provided a business update. Notable developments since April 1st include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Bioscienc

    8/14/25 8:46:00 AM ET
    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference

    SAN DIEGO, Aug. 5, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCID: EVFM) is proud to announce that its CEO, Saundra Pelletier, will be honored with the Trailblazing Female Founders Award at the 2025 STIMULATE Conference, the premier U.S. sexual wellness industry event. The award will be presented today, August 5, 2025, during the conference held in Nashville, Tennessee. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> The STIMULATE Conference is North America's only trade sho

    8/5/25 8:46:00 AM ET
    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVFM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Zhang Yan sold $4 worth of shares (104 units at $0.04), closing all direct ownership in the company (SEC Form 4)

    4 - Evofem Biosciences, Inc. (0001618835) (Issuer)

    1/12/24 5:13:24 PM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamdar Kim P. sold $6 worth of shares (10 units at $0.62), closing all direct ownership in the company (SEC Form 4)

    4 - Evofem Biosciences, Inc. (0001618835) (Issuer)

    12/22/23 4:05:30 PM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 5 filed by File Justin J.

    5 - Evofem Biosciences, Inc. (0001618835) (Issuer)

    5/8/23 4:05:19 PM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVFM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley reiterated coverage on Evofem Biosciences with a new price target

    Morgan Stanley reiterated coverage of Evofem Biosciences with a rating of Underweight and set a new price target of $0.53 from $0.50 previously

    3/4/22 8:06:41 AM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Evofem Biosciences with a new price target

    HC Wainwright & Co. reiterated coverage of Evofem Biosciences with a rating of Buy and set a new price target of $2.00 from $2.50 previously

    11/16/21 9:42:11 AM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Evofem Biosciences with a new price target

    HC Wainwright & Co. reiterated coverage of Evofem Biosciences with a rating of Buy and set a new price target of $2.50 from $4.00 previously

    10/21/21 6:49:27 AM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVFM
    SEC Filings

    View All

    SEC Form 10-Q filed by Evofem Biosciences Inc.

    10-Q - Evofem Biosciences, Inc. (0001618835) (Filer)

    8/14/25 8:50:12 AM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evofem Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Evofem Biosciences, Inc. (0001618835) (Filer)

    8/14/25 8:48:40 AM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PREM14A filed by Evofem Biosciences Inc.

    PREM14A - Evofem Biosciences, Inc. (0001618835) (Filer)

    7/24/25 4:06:11 PM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVFM
    Leadership Updates

    Live Leadership Updates

    View All

    Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

    Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Dr. Charles Howe, Chair of the Division of Experimental Neurology and Director of Research at the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, will join the Aditxt Weekly Update on May 2, 2025, to discuss key findings from the newly announced preclinical study evaluating ADI-100™, the lead therapeutic candidate developed by its wholly owned subsidiary, Adimune™, Inc. ("Adimune"). Featured participants will include Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt, Inc., and Dr. Friedrich Kapp, Co-Chief Executive Offic

    4/17/25 8:15:00 AM ET
    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives

    Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced the appointment of Sylvia Hermina to its Board of Directors. With over 20 years of experience advising public companies on corporate governance, mergers and acquisitions, and shareholder relations, Ms. Hermina brings a wealth of expertise in fostering effective and impactful engagement between management teams and stakeholders. Throughout her career, Ms. Hermina has advised NYSE and NASDAQ listed companies on governance best practices and developed communication strategies tailored to retail and institutional investors. As Senior Vice

    10/29/24 8:15:00 AM ET
    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aditxt's Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)

    Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), appointed Christoper Mitton as President. Christopher Mitton brings over 20 years of leadership experience in the medical diagnostics industry, with a strong focus on personalized healthcare and molecular oncology diagnostics. He has a proven track record in building and leading successful commercial operations, underpinned by his deep expertise in product commercialization, business development, and strategic sales and marketing. Mr. Mitton continues to serve as

    8/26/24 8:15:00 AM ET
    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVFM
    Financials

    Live finance-specific insights

    View All

    Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

    -- Increased Net Sales and Improved Loss from Operations in Q2 2025 vs. Prior Year Quarter -- -- Evofem Advances Plans for Special Meeting of Stockholders to Approve the A&R Merger Agreement and Become a Wholly-owned Subsidiary of Aditxt --  SAN DIEGO, Aug. 14, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the three- and six-month periods ended June 30, 2025 and provided a business update. Notable developments since April 1st include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Bioscienc

    8/14/25 8:46:00 AM ET
    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evofem Reports First Quarter 2025 Financial Results and Provides Business Update

    SAN DIEGO, May 15, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM), today announced financial results for the first quarter ended March 31, 2025. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> "Quarterly fluctuations are normal for our business, which is why we focus on driving annual growth," said Saundra Pelletier, Evofem's CEO. "First quarter net sales were soft, as expected, due to the high level of PHEXXI stocking orders in the fourth qua

    5/15/25 7:59:00 AM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

    WARRINGTON, Pa., April 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the fiscal year ended December 31, 2024 and provided key business updates. "The year 2024 saw Windtree make great progress in many key areas including clinical development of our lead drug candidate istaroxime in cardiogenic shock, business development and the future strategy of the Company," said Jed Latkin, CEO of Windtree. "Cardiogenic shock is a critical condition with high morbidity and mortality where clinician

    4/15/25 8:00:00 AM ET
    $EVFM
    $WINT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $EVFM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Evofem Biosciences Inc. (Amendment)

    SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)

    2/14/24 2:14:48 PM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Evofem Biosciences Inc. (Amendment)

    SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)

    2/14/23 11:24:47 AM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Evofem Biosciences Inc. (Amendment)

    SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)

    8/10/22 4:17:03 PM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care